NMDA receptor hypofunction model of schizophrenia

Journal of Psychiatric Research

Volumn 33, Issue 6, 1999, Pages 523-533

  Olney, John W ^a   Newcomer, John W ^a   Farber, Nuri B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neurodegeneration; NMDA receptors; Prevention; Psychosis; Rat model; Schizophrenia; Treatment

Indexed keywords

BIOCHEMICAL MARKER; DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

BRAIN DEVELOPMENT; DOPAMINERGIC SYSTEM; HUMAN; HYPOTHESIS; MODEL; NERVE CELL NETWORK; NERVE DEGENERATION; NERVOUS SYSTEM FUNCTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0032694066     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(99)00029-1     Document Type: Article

References (64)

1. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. Journal of Neuroscience. 18:1998;5545-5554.
2. Anand A., Charney D.S., Berman R.M., Oren D.A., Cappiello A., Krystal J.H. Reduction in ketamine effects in humans by lamotrigine. Society for Neuroscience Abstracts. 23:1997;1755.
3. Carpenter W.R. Jr, Buchanan R.W., Kirkpatrick B., Breier A.F. Diazepam treatment of early signs of exacerbation in schizophrenia. American Journal of Psychiatry. 156:1999;299-303.
4. Cohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Archives of General Psychiatry. 6:1962;395-401.
5. Corso T.D., Sesma M.A., Tenkova T.I., Der T.C., Wozniak D.F., Farber N.B., Olney J.W. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Research. 752:1997;1-14.
6. Domino E.F., Luby E.D. Abnormal mental states induced by phencyclidine as a model of schizophrenia. Domino E.F. PCP (Phencyclidine): historical and current perspectives. 1981;401-418 NPP Books, Ann Arbor.
7. Dundee J.W., Lilburn J.K. Ketamine-lorazepam: attenuation of psychic sequelae of ketamine by lorazepam. Anaesthesia. 33:1978;312-314.
8. Ellison G. Competitive and noncompetitive NMDA antagonists induce similar limbic degeneration. Neuroreport. 5:1994;2688-2692.
9. Ellison G., Switzer R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport. 5:1993;17-20.
10. Famy C., Streissguth A.P., Unis A.S. Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. American Journal of Psychiatry. 155:1998;552-554.
11. 2 adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology. 12:1995;347-349.
12. Farber N.B., Foster J., Duhan N.L., Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophrenia Research. 21:1996;33-37.
13. 2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology. 18:1998;57-62.
14. Farber N.B., Kim S.H., Olney J.W. Costimulation of muscarinic and nonNMDA glutamate receptors reproduces NMDA antagonist neurotoxicity. Society for Neuroscience Abstracts. 23:1997;2308.
15. Farber N.B., Price M.T., Labruyere J., Nemnich J., St Peter H., Wozniak D.F., Olney J.W. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biological Psychiatry. 34:1993;119-121.
16. Farber N.B., Wozniak D.F., Price M.T., Labruyere J., Huss J., St Peter H., Olney J.W. Age specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biological Psychiatry. 38:1995;788-796.
17. Fix A.S., Wightman K.A., O'Callaghan J.P. Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunohistochemistry. Neurotoxicology. 16:1995;229-239.
18. Giovannini M.G., Camilli F., Mundula A., Pepeu G. Glutamatergic regulation of acetylcholine output in different brain regions: a microdialysis study in the rat. Neurochemistry International (Oxford). 25:1994;23-26.
19. Greengard P., Nairn A.C., Girault J.A., Ouimet C.C., Snyder G.L., Fisone G., Fienberg A., Nishi A. The DARPP-32/protein phosphatase-1 cascade: a model for signal integration. Brain Research: Brain Research Reviews. 26:1998;274-284.
20. Grotta J., Clark W., Coull B., Pettigrew L.C., Mackay B., Goldstein L.B., Murphy D., LaRue L. Safety and tolerability of the glutamate antagonist CGS 5 (Selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke. 26:1995;602-605.
21. Hasegawa M., Kinoshita H., Amano M., Hasegawa T., Kameyama T., Nabeshima T. MK-801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis. Neuroscience Letters. 150:1993;53-56.
22. Herrling P. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from animal models and first results in humans. Neuropsychopharmacology. 10(3S/Part 1):1994;591S.
23. Hollister L.E., Müller-Oerlinghausen B., Rickels K., Shader R.I. Clinical use of benzodiazepines. Journal of Clinical Psychopharmacology. 13:(Suppl. 1):1993;1S-169S.
24. Horvath Z.C., Czopf J., Buzsaki G. MK-801-induced neuronal damage in rats. Brain Research. 753:1997;181-195.
25. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Stefovska V., Turski L., Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 283:1999;70-74.
26. Ikonomidou C., Price M.T., Mosinger J.L., Frierdich G., Labruyere J., Salles K.S., Olney J.W. Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain. Journal of Neuroscience. 9:1989;1693-1700.
27. Ishimaru M., Fukamauchi F., Olney J.W. Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex. Neuroscience Letters. 193:1995;1-4.
28. Jakab R.L., Goldman-Rakic P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proceedings of the National Academy of Sciences of the United States of America. 95:1998;735-740.
29. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry. 148:1991;1301-1308.
30. Jevtovic-Todorovic V., Kirby C.O., Olney J.W. Isoflurane and propofol block neurotoxicity caused by MK-801 in the rat posterior cingulate/retrosplenial cortex. Journal of Cerebral Blood Flow and Metabolism. 17:1997;168-174.
31. Kim SH, Price MT, Olney JW, Farber NB. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and 2-adrenergic agonists. Molecular Psychiatry 1999 (in press).
32. Kristensen J.D., Svensson B., Gordh T. Jr. The NMDA receptor-antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain. 51:1992;249-253.
33. Krystal J.H., Karper L.P., Bennett A., D'Souza D.C., Abi-Dargham A., Morrissey K., Abi-Saab D., Bremner J.D., Bowers M.B. Jr., Suckow R.F., Stetson P., Heninger G.R., Charney D.S. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology. 135:1998;213-229.
34. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr, Vegso S, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 1999; (in press).
35. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive and neuroendocrine responses. Archives of General Psychiatry. 51:1994;199-214.
36. Lodge D., Anis N.A. Effects of phencyclidine on excitatory amino acid activation of spinal interneurones in the cat. European Journal of Pharmacology. 77:1982;203-204.
37. Lodge D., Aram J.A., Church J., Davies S.N., Martin D., O'Shaughnessey C.T., Zeman S. Excitatory amino acids and phencyclidine-like drugs. Hicks T.P., Lodge D., McLennan H. Excitatory amino acid transmission. 1987;83-90 Alan R. Liss Inc, New York.
38. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug: Sernyl. Archives of Neurology and Psychiatry. 81:1959;363-369.
39. Magbagbeola J.A., Thomas N.A. Effect of thiopentone on emergence reactions to ketamine anaesthesia. Canadian Anaesthesia Society Journal. 21:1974;321-324.
40. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biological Psychiatry. 42:1997;664-668.
41. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
42. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience. 17:1997;2921-2927.
43. Mrzljak L., Levey A.I., Belcher S., Goldman-Rakic P.S. Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey. Journal of Comparative Neurology. 390:1998;112-132.
44. Muir K.W., Grosset D.G., Lees K.R. Effects of prolonged infusion of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. Clinical Neuropharmacology. 20:1997;311-321.
45. Muly E.C., Szigeti K., Goldman-Rakic P.S. D1 receptor in interneurons of macaque prefrontal cortex: distribution and subcellular localization. Journal of Neuroscience. 18:1998;10553-10565.
46. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Kelly Melson A., Hershey T., Craft S., Olney J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment in schizophrenia. Neuropsychopharmacology. 20:1999;106-118.
47. Newcomer J.W., Farber N.B., Selke G., Melson A.K., Jevtovic-Todorovic V., Olney J.W. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Society for Neuroscience Abstracts. 24:1998;525.
48. Newcomer JW, Selke G, Melson A, White DA, Roediger HL, Farber NB, Wozniak DF, Jevtovic-Todorovic V, Olney JW. NMDA antagonist-induced decreases in working and explicit memory in humans. Society for Neuroscience Abstracts 1999b;25 (in press).
49. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry. 52:1995;998-1007.
50. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
51. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 254:1991;1515-1518.
52. Olney J.W., Wozniak D.F., Price M.T., Ikonomidou C. Alcohol induces massive apoptotic neurodegeneration in the developing rat CNS. Society for Neuroscience Abstracts. 24:1998;1983.
53. Olney JW, Wozniak DF, Price MT, Tenkova TI, Dikranian K, Ikonomidou C. Ethanol induces widespread apoptotic neurodegeneration in the infant mouse brain. Society for Neuroscience Abstracts 1999;25 (in press).
54. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 2 :1986;Academic Press, New York.
55. Price MT, Wozniak DF, Tenkova TI, Dikranian K, Ikonomidou C, Olney JW. Ethanol induces widespread apoptotic neurodegeneration in the fetal guinea pig brain. Society for Neuroscience Abstracts 1999;25 (in press).
56. Reich D.L., Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Canadian Journal of Anaesthesia. 36:1989;186-197.
57. Rosenbaum G., Cohen B.D., Luby E.D., Gottlieb J.S., Yelen D. Comparison of Sernyl with other drugs. Archives of General Psychiatry. 1:1959;651-656.
58. Tandon R., Greden J.F. Cholinergic hyperactivity and negative schizophrenic symptoms: a model of cholinergic/dopaminergic interactions in schizophrenia. Archives of General Psychiatry. 46:1989;745-753.
59. Tandon R., Shipley J.E., Greden J.F., Mann N.A., Eisner W.H., Goodson J.A. Muscarinic cholinergic hyperactivity in schizophrenia: relationship to positive and negative symptoms. Schizophrenia Research. 4:1991;23-30.
60. White P.F., Way W.L., Trevor A.J. Ketamine: its pharmacology and therapeutic uses. Anesthesiology. 56:1982;119-136.
61. Williams S.M., Goldman-Rakic P.S. Widespread origin of the primate mesofrontal dopamine system. Cerebral Cortex. 8:1998;321-345.
62. Wolkowitz O.M., Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. American Journal of Psychiatry. 148:1991;714-726.
63. Wozniak D.F., Dikranian K., Ishimaru M., Nardi A., Corso T.D., Tenkova T.I., Olney J.W., Fix A.S. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease. Neurobiology of Disease. 5:1998;305-322.
64. Yesavage J.A., Freeman A.M. III. Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. Journal of Clinical Psychiatry. 44:1978;664-665.